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The addition of hyperthermia (HT) to regional isolated perfusion (RIP) with Melphalan theoretically 
has two advantages. Firstly, heat can selectively kill cells in poorly vascularised areas that are 
usually not reached by the drug. Secondly, in vitro data have revealed that the effect of Melphalan 
is enhanced at temperatures 39-45°C. However, for the simultaneous application of Melphalan and 
HT, as it is given in most institutes, both normal and tumour tissues within the volume are treated 
with both modalities. It is unclear whether-for the same heat dose-the cytoxicity of Melphalan is 
enhanced more in tumour tissue than in normal tissues. As the applied dose of Melphalan in RIP is 
selected on maximum acceptable toxicity, any enhancement of toxicity is undesired. Indeed, Melpha- 
lan application at temperatures >41”C has resulted in unacceptable toxicity. In most institutes, the 
hyperthermia dose is reduced in comparison to application as a single-modality treatment, to allow 
simultaneous combination without unacceptable toxicity. In this review, the rationale for two differ- 
ent approaches is summarised which may make it possible to improve the benefit from the theoreti- 
cal advantage of the use of HT in RIP. It is meant to stimulate discussion as a possible first step in 
the design of new treatment protocols. 0 1997 Elsevier Science Ltd. 
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INTRODUCTION 
REGIONAL ISOLATED perfusion (RIP) with Melphalan and 
hyperthermia (HT) is a generally accepted treatment for 
locally or regionally advanced melanoma of an extremity. 
However, the role of HT in RIP with Melphalan, and the 
optimum schedule for combining the two modalities, are 
not well defined. Reports of better results from current HT 
perfusions in comparison with those from earlier studies 
may have to be explained by the fact that in those early 
days no special measures were taken to prevent the limb 
from cooling down during preparative surgery. Tissue tem- 
peratures of the limb were probably as low as 30°C [l]. 
In view of this, the comparison is between hyper- and 
hypothermia, a condition which probably interferes with the 
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exposure of tumour cells to chemotherapy. This background 
is the reason that the members of the ‘AmRo perfusion 
team’, a co-operative group from both the Dr Daniel den 
Hoed Cancer Center in Rotterdam and The Netherlands 
Cancer Institute in Amsterdam, have chosen to apply RIP 
with Melphalan at controlled normothermic (37-38°C) 
temperatures [2]. 
However, HT is an interesting modality in the treatment 
of cancer. Recently, the therapeutic gain by HT in addition 
to radiotherapy, was proven by randomised comparative stu- 
dies for various types of tumour [3-61. Both experimental 
and clinical data indicate that the application of HT results 
in tumour cell kill at dose levels which are not toxic to 
normal tissues. HT is especially toxic to cells in insuffi- 
ciently perfused areas of tumours, which are hypoxic and 
acidic [7, 81. HT has a greater effect on tumour tissue than 
on normal tissue due to the indirect effects of inducing vas- 
cular stasis. Such vascular stasis is caused by heat damage 
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to endothelial cells; up to a certain HT dose level, the high 
proliferation rate of endothelial cells in tumours renders 
them more sensitive to HT than ‘normal’ endothelial cells 
that have slower proliferation rates [9]. Unfortunately, 
(heat-induced) stasis may also have a counteracting effect as 
it will lead to reduced drug penetration in insufficiently per- 
fused areas. Moreover, HT may also enhance drug toxicity 
to normal tissues. When Melphalan is applied at the dose 
which is maximally tolerable in normothermic RIP, this 
leads to unacceptable toxicity, as was indeed found to be 
true in some clinical trials (see Section CZinicaZ data). 
Two different approaches to circumvent the problem of 
thermal enhancement of normal tissue toxicity are 
suggested. The first is to use only the complementary action 
of heat (specific killing of drug-resistant cells in poorly vas- 
cularised areas) by sequential application in two RIP treat- 
ments with a one week interval. The second is to reduce the 
drug dose in a simultaneous application and benefit from 
both the preferential effect that HT has on cells in poorly 
perfused areas and the enhancement of drug cytotoxicity. 
EFFECT OF COMBINED MELPHALAN AND 
HYPERTHERMIA 
Preclinical data 
Experimental data have shown that the cytotoxicity of 
Melphalan increases with higher temperatures, beginning at 
temperatures as mild as 39-40°C [lo, 111. Thermal 
enhancement was found to be rapidly lost with an increas- 
ing time interval between the two treatments [lo]. 
In cancer treatment, it is important to achieve a thera- 
peutic gain, i.e. more enhancement of cytotoxicity to the 
tumour tissue compared to normal tissues. There is only 
limited information concerning therapeutic gain with regard 
to simultaneous combination of Melphalan and HT. For 
simultaneous combination of Melphalan and whole body 
HT (45 min at 41°C using a rat model), the thermal 
enhancement ratio (TER, defined as the ratio of the drug 
dose required to produce a certain biological effect and the 
drug dose which in combination with HT leads to the same 
effect) for tumour growth delay varied from 2 to 4.3 [ 121. 
For bone marrow toxicity, the TER varied from 1.7 to 2.9. 
In a study in dogs with spontaneous malignant melanoma, 
whole body HT of 60 min at 41.9-42°C enhanced the prob- 
ability of severe haematological toxicity from Melphalan 
with a factor of 1.9, whereas no improvement in tumour re- 
sponse was found in the combined treated group [13]. 
These results emphasise that normal tissue toxicity is ex- 
acerbated by simultaneous application of Melphalan and 
HT. Since the relatively mild HT temperature do not 
induce such effects in normal tissue when applied as a single 
treatment (see below), it must be concluded that these are 
the result of thermal enhancement of drug toxicity. A thera- 
peutic gain is not achieved as a rule by the simultaneous 
combination of whole body HT and systemic application of 
Melphalan. Similar types of problems may also be encoun- 
tered when using RIP, but this has not been tested in ani- 
mals. 
Clinical data 
Clinical data indicate that simultaneous combination of 
high doses of Melphalan and HT results in unacceptable 
toxicity. Whereas Vaglini and associates, in their early stu- 
dies [14], administered Melphalan at tissue temperatures of 
42.5-43”C, they later reported that the temperature should 
be below 41.5”C to avoid too severe complications [15]. As 
revealed by a logistic regression model of a series of patients 
treated with RIP in Amsterdam and Rotterdam [ 161, one of 
the factors associated with more severe toxicity was tissue 
temperature of 40°C or higher. The AmRo perfusion group 
applied simultaneous HT (41-42°C) and Melphalan to 11 
patients with malignant melanoma. Melphalan was added 
slowly (over 1 circulation time) to the perfusate when the 
tissue temperatures had reached 41°C. The Melphalan dose 
was 10 mg/l perfused tissue for leg perfusions and 13 mgil 
for arm perfusions. The toxicity of this regimen was unac- 
ceptably severe [ 171. In 1 patient, amputation was un- 
avoidable after development of a compartmental syndrome 
and tissue necrosis. In 5 patients, irreversible functional 
impairment of the treated limb resulted, due to paralysis of 
the peroneal nerve and/or fibrosis or ankylosis. 
Generally, however, severe toxicity following hyperther- 
mic RIP occurs less frequently. In 2966 treated patients, 
overall functional impairment of the limb occurred in 4.2% 
of the patients and amputation was necessary in O-6% 
(overall 1%) of the patients (Cavaliere and associates [l 81). 
The only publication reporting amputation in 6% is that by 
Vaglini and associates [14] on perfusion at tissue tempera- 
tures of 42.5-43°C. The higher toxicity in our own study, 
compared to other published results, was suggested to be 
due to the high tissue temperatures at the time of 
Melphalan administration [17]. From other reports, it can 
be derived that the level of similar high temperatures is 
reached only in the course of the cytostatic perfusion. By 
that time, the Melphalan concentration has already 
decreased by 40-45%, leaving less drug available for ther- 
mal enhancement of drug cytotoxicity. 
Table 1. Regional isolated pe+ion: complete response rates reported for melanoma 
Tissue 
Reference CRs n % temperature 
Kroon and associates [20] 7118 
Kroon and associates [25] (two normothermic RIPS) 33143 
Rosin and Westbury [21] 21180 
Lejeune and associates [22] 15123 
Vaglini and associates [ 151 18132 
Storm and Morton [23] 21126 
Di Filippo and associates [24] 27169 
Kroon and associates [ 171 7111 
Kroon and associates [I91 (sequential application) 9/10 
39 37-38 C 
77 37-38 C 
26 39-40-c 
65 39-41 c 
56 40-41 c 
81 40-41.8’C 
39 41-42’C 
64 41-42’C 
90 42-43 C 
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Table 2. Normal tissue tolerance to hyperthemia 
Tissue type Species 
Dose 
Time (min) Temp. (‘C) Damage 
Skin 
Subcutaneous fat 
Muscle 
Nerve 
Lymph node 
Whole limb 
mouse [27] 
mouse [28] 
pig [291 
human [29] 
pig [301 
pig [311 
pig 1301 
pig ]311 
rat [32] 
rat [33] 
dog [34, 351 
rat [36] 
dog ]371 
human [19] 
60 43 
15 44 
150 45 
120 45 
30 45 
20-40 47 
30 45 
20-40 47 
30 43 
37.5 43 
60 43-44 
30 45 
120 42-44 
120 42-43 
none 
oedema, recovered in 2 days 
mild hyperaemia 
hyperaemia 
mild changes 
minimum 
mild changes 
minimum 
none 
mild, recovered in 4 weeks 
mild, recovered in 3 weeks 
minimum 
no major damage 
none, when normal tissue hypoxia was prevented 
In Table 1, published complete response rates following 
RIP are summarised [ 15, 17, 19-251. Overall, complete re- 
sponse rates achieved with perfusion at tissue temperatures 
of 340°C range from 36 to 81%. The 39% complete re- 
sponse rate following normothermic RIP reported by Kroon 
and associates [20] is not significantly lower than that pro- 
duced by most of the mild (39-40°C) or true (41-42°C) 
hyperthermic RIPS. In only one publication, a significant 
higher complete response rate was reported [23]. Following 
a schedule applying two separate normothermic RIPS with 
Melphalan, a complete response rate of 77% was achieved 
[25]. The simultaneous administration of ‘true’ HT as 
applied by Kroon and associates [ 171 resulted in a 64% 
complete response rate, but, as mentioned before, this treat- 
ment regimen was discontinued because of unacceptable 
toxicity. 
Limb recurrence-free intervals and overall survival were 
compared retrospectively for two groups of patients treated 
in The Netherlands and Belgium with either ‘controlled 
normothermic’ or ‘mild’ hyperthermic RIP following exci- 
sion of tumour lesions. Controlling for a variety of prognos- 
tic factors, the application of ‘mild’ HT did not influence 
limb recurrence-free interval nor survival [26]. 
NORMAL TISSUE TOLERANCE TO 
HYPERTHERMIA 
It is unlikely that the toxicity observed following ‘true’ 
hyperthermic Melphalan RIPS is due to the effect of heat 
alone. A summary of results on normal tissue tolerance to 
HT which are relevant for a limb is given in Table 2 [ 19, 
27-371. Skin, fat and muscle tissues of a pig are not severely 
damaged by a heat dose of 30 min at 45°C. This heat dose 
is equivalent to 120 min at 43°C [38]. Peripheral nervous 
tissue may be somewhat more sensitive to hyperthermia, but 
toxicity appears acceptable (rapidly reversible) for HT treat- 
ments up to 60 min at 44’C. Limb perfusion in dogs was 
tolerated without irreversible damage up to a dose of 2 h at 
42-44°C [37] and in humans an HT dose of 2 h at 42- 
43°C without Melphalan was found to be safe, provided 
that pressure on the normal tissues was avoided, which 
otherwise might have caused normal tissue hypoxia [ 191. 
DOUBLE PERFUSIONS WITH SEQUENTIAL 
APPLICATION OF HEAT AND MELPHALAN: 
FIRST CLINICAL EXPERIENCE 
In order to avoid the risk of unacceptable normal tissue 
toxicity following simultaneous application of heat and 
Melphalan, but still benefit from the ability of heat to be 
complementary to Melphalan, sequential applications of 
high-dose HT (2 h at 42-43°C) and Melphalan perfusion 
1 week later has been applied to 10 patients with locally in- 
operable recurrent melanoma [ 191. A complete response 
was achieved in 9 patients, whilst 1 patient showed a partial 
response. Impressive tumour regressions and central tumour 
necrosis were found in most of the patients within 1 week 
following HT perfusion; one example is given in Figure 1. 
The median duration of complete response was 5+ (3+-12+) 
months. Two patients developed a recurrence in the per- 
fused region, both after 5 months. The schedule was well 
tolerated with few side-effects. It can be deduced from these 
initial data that the extra perfusion with heat alone may lead 
to better tumour control than normothermic or ‘mild’ HT 
RIP with Melphalan (see Table 1). However, the major dis- 
advantage of the sequential combination is that it requires 
two surgical procedures. 
MORE HEAT, LESS DRUG: AN’ ALTERNATIVE 
APPROACH 
Another approach, in which both the disadvantage of the 
two surgical procedures can be avoided and the advantage 
of optimum use of the two treatment modalities may be 
exploited, would be to administer HT at the maximum tol- 
erated level, and reduce the simultaneously administered 
Melphalan dose on the basis of the maximum acceptable 
toxicity at that temperature. The only assumption made for 
this approach is that, for the same heat dose, the cytoxicity 
of Melphalan is equally enhanced in well-perfused tumour 
tissue compared to normal tissues. With this assumption, 
the biological rationale for the ‘more heat-less drug 
approach’ is as follows. 
1. The normal tissue toxicity remains within acceptable 
levels, since the Melphalan dose is reduced according to 
the enhancement obtained by the simultaneous heat 
treatment. Such a new tolerance dose should be derived 
from phase I studies. Yet, it already has been suggested 
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Figure 1. Histopathology of a tumour nodule excised immediately before perfusion of Melphalan, 1 week after RIP for 2 h at 
42.5’C in a patient with multiple in transit metastases of malignant melanoma. The tumour centre has become necrotic, cells 
in the tumour periphery and the nearby skin are vital, demonstrating the preferential effect of HT in part of the tumour. 
that the Melphalan dose to be given is 12 mg/l perfused 
tissue when tissue temperatures are increased to 41.5‘ C 
or higher, whereas it can be 14 mgil perfused tissue at a 
temperature of 39’ C [ 181. 
2. As a consequence of our assumption, the antitumour 
efficacy of this approach in well-perfused tumour tissues 
is similar to that achieved with ‘standard’ application. 
3. The main beneficial effect of this approach concerns the 
cells in insufficiently perfused parts of the tumour. In 
view of the experience with HT alone in the sequentially 
applied combination, an HT dose of 2 h at approxi- 
mately 42.5’C is highly effective. Putative negative 
effects of HT-induced stasis [9] on drug penetrance, if 
occurring at all during treatment, are likely to be com- 
pensated for by the preferential heat kill of cells in these 
areas of vascular occlusion and by the drug sensitisation 
effect. 
As both drug and heat cytotoxicity are used at ‘full’ ca- 
pacity, that is, to the limits of tolerance, in theory this 
approach can be expected to give similar good responses 
compared to the sequential combination of HT and 
Melphalan. 
CONCLUSION 
The application of HT in perfusion falls into one of three 
categories: ‘controlled normothermia’ (tissue temperatures 
between 37 and 38-C), ‘mild’ HT (39-40°C) and ‘true’ 
HT (41.5-43 C). ‘Controlled normothermic’ perfusion 
focuses on the effect of the cytostatic drug alone. ‘Mild’ HT 
may, to some extent, potentiate the cytostatic effect of 
Melphalan [ 121, although the clinical data do not support 
this notion. Perfusions with ‘true’ HT without alterations in 
scheduling or adaptations in drug dose lead to unacceptable 
toxicity due to heat and drug interaction. Yet, true HT is 
tolerable and may lead to better tumour control if applied 
separately from Melphalan. When the two treatment modal- 
ities are combined sequentially, both HT and Melphalan 
can be administered at optimum levels. True HT perfusion 
will kill cells in the hypoxic parts of the tumour, without 
causing normal tissue toxicity. The second normothermic 
perfusion with Melphalan will attack the residual well-per- 
fused parts of the tumour. However, the need for two surgi- 
cal procedures is a major disadvantage. As an alternative 
approach, it is suggested that a maximally tolerated HT 
treatment is applied simultaneously with a reduced dose of 
Melphalan. With the appropriate dose reduction (based on 
the enhancement factor for drug toxicity), this (a) should 
not compromise the effect of the drug in well-perfused 
tumour areas; (b) should not lead to an unacceptable tox- 
icity in normal tissues; (c) maximally utilises the selective 
effect of HT in poorly perfused areas of the tumour; and 
(d) require only one surgical procedure. Such an approach 
deserves further attention. 
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There should be discussion on this topic, since the simul- 
taneous combination of Melphalan and HT in RIP as cur- 
rently applied in most institutes may be far from optimal. 
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